Objective: The objective of this study was to evaluate the predictive value of inflammatory biomarkers (CRP, IP-10, IL-6, TNF-α) in determining treatment outcomes in drug-resistant tuberculosis (DR-TB) patients. Methodology: This study, conducted on 20 DR-TB patients, was monitored for biomarker levels at baseline and during treatment. Descriptive statistics, correlation analysis, logistic regression, and Kaplan-Meier survival analysis were applied to assess the relationship between biomarker levels and treatment outcomes. The statistical significance of the biomarkers in predicting time to sputum smear and culture conversion was evaluated, and sensitivity analysis was conducted across different patient subgroups. Results: Elevated baseline levels of CRP, IP-10, IL-6, and TNF-α were significantly associated with prolonged time to sputum smear and culture conversion. Logistic regression analysis revealed that these biomarkers independently predicted favorable treatment outcomes. Kaplan-Meier survival curves showed that patients with higher baseline biomarker levels experienced delayed treatment responses. Sensitivity analysis indicated increased sensitivity of these biomarkers in males and patients with higher baseline bacterial loads. Conclusion: CRP, IP-10, IL-6, and TNF-α are valuable biomarkers for predicting treatment success in DR-TB patients. Their predictive power suggests potential for improving personalized treatment strategies, allowing for earlier identification of patients who may require more intensive or prolonged therapies. Further studies with larger cohorts are necessary to validate these findings and expand the biomarker profile to enhance treatment predictions in DR-TB cases.